StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

Equities research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $1.67 on Tuesday. The business’s 50 day moving average price is $2.32 and its 200-day moving average price is $4.33. Evogene has a 1 year low of $1.44 and a 1 year high of $10.40. The firm has a market capitalization of $8.97 million, a price-to-earnings ratio of -0.37 and a beta of 1.43.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.